Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,032 | 56 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $397.09 | 22 | $0 (2023) |
| Medtronic, Inc. | $144.95 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $133.16 | 10 | $0 (2019) |
| PFIZER INC. | $99.86 | 7 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $87.22 | 5 | $0 (2019) |
| Intercept Pharmaceuticals, Inc. | $39.30 | 3 | $0 (2019) |
| UCB, Inc. | $36.46 | 2 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.47 | 2 | $0 (2020) |
| Lilly USA, LLC | $22.11 | 1 | $0 (2024) |
| Shire North American Group Inc | $20.08 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22.11 | 1 | Lilly USA, LLC ($22.11) |
| 2023 | $228.15 | 2 | Medtronic, Inc. ($144.95) |
| 2022 | $47.83 | 1 | ABBVIE INC. ($47.83) |
| 2021 | $13.26 | 1 | Celgene Corporation ($13.26) |
| 2020 | $39.63 | 3 | PFIZER INC. ($28.16) |
| 2019 | $247.79 | 17 | Janssen Biotech, Inc. ($64.33) |
| 2018 | $238.67 | 16 | AbbVie, Inc. ($81.37) |
| 2017 | $194.13 | 15 | AbbVie, Inc. ($120.49) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Immunology | ||||||
| 11/07/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $83.20 | General |
| Category: IMMUNOLOGY | ||||||
| 03/24/2023 | Medtronic, Inc. | GI GENIUS (Device) | Food and Beverage | In-kind items and services | $144.95 | General |
| Category: Gastrointestinal AI | ||||||
| 09/28/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $47.83 | General |
| Category: IMMUNOLOGY | ||||||
| 06/14/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.26 | General |
| Category: Neuroscience | ||||||
| 09/23/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/24/2020 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/13/2020 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Immunology | ||||||
| 12/04/2019 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/25/2019 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 10/23/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $11.91 | General |
| Category: Immunology | ||||||
| 10/22/2019 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/25/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Lower GI | ||||||
| 09/23/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2019 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: Immunology | ||||||
| 08/29/2019 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/07/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Immunology | ||||||
| 06/19/2019 | Janssen Biotech, Inc. | STELARA (Biological), SIMPONI | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: Immunology | ||||||
| 06/05/2019 | Janssen Biotech, Inc. | STELARA (Biological), SIMPONI | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: Immunology | ||||||
| 05/01/2019 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/23/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $15.72 | General |
| 03/06/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Immunology | ||||||
| 02/06/2019 | AbbVie, Inc. | Creon (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Endocrinology | ||||||
| 01/17/2019 | Janssen Biotech, Inc. | STELARA (Biological), SIMPONI | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 315 | 362 | $127,717 | $38,627 |
| 2022 | 9 | 320 | 355 | $113,399 | $36,441 |
| 2021 | 11 | 450 | 507 | $216,905 | $54,021 |
| 2020 | 10 | 440 | 527 | $204,801 | $52,365 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 61 | 61 | $37,515 | $11,636 | 31.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 42 | $14,700 | $5,392 | 36.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 65 | 69 | $23,115 | $5,074 | 22.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 65 | $8,190 | $3,960 | 48.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 22 | 22 | $9,900 | $3,870 | 39.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 43 | 43 | $20,941 | $3,693 | 17.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 14 | 14 | $6,314 | $2,468 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 33 | $6,171 | $2,034 | 33.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 13 | $871.00 | $499.07 | 57.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 61 | 64 | $22,400 | $9,530 | 42.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 32 | 32 | $19,680 | $6,306 | 32.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 70 | 71 | $23,785 | $5,610 | 23.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 83 | $10,458 | $4,555 | 43.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 15 | 15 | $6,750 | $2,682 | 39.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 22 | 22 | $9,900 | $2,618 | 26.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 26 | 26 | $12,662 | $2,314 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 27 | $5,049 | $1,645 | 32.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 15 | $2,715 | $1,182 | 43.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 93 | 96 | $31,695 | $15,195 | 47.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 42 | 43 | $41,242 | $7,999 | 19.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 81 | 120 | $13,538 | $6,875 | 50.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 55 | 56 | $41,369 | $6,193 | 15.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 69 | 69 | $42,793 | $5,928 | 13.9% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 29 | 29 | $20,262 | $3,434 | 16.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 15 | 15 | $8,650 | $2,741 | 31.7% |
About Dr. Heidi Putt, DO
Dr. Heidi Putt, DO is a Internal Medicine healthcare provider based in Wyoming, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114969888.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heidi Putt, DO has received a total of $1,032 in payments from pharmaceutical and medical device companies, with $22.11 received in 2024. These payments were reported across 56 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,032).
As a Medicare-enrolled provider, Putt has provided services to 1,525 Medicare beneficiaries, totaling 1,751 services with total Medicare billing of $181,455. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Wyoming, MI
- Active Since 06/10/2006
- Last Updated 05/27/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1114969888
Products in Payments
- Humira (Biological) $204.48
- GI GENIUS (Device) $144.95
- STELARA (Biological) $133.16
- XELJANZ (Drug) $99.86
- SKYRIZI (Biological) $83.20
- Entyvio (Biological) $71.50
- Creon (Drug) $61.58
- RINVOQ (Biological) $47.83
- Cimzia (Drug) $36.46
- OCA (Drug) $24.63
- XIFAXAN (Drug) $24.47
- OMVOH (Drug) $22.11
- GATTEX (Drug) $20.08
- OCALIVA (Drug) $14.67
- ZEPOSIA (Drug) $13.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Wyoming
Mounir Ghali, M.d, M.D
Internal Medicine — Payments: $363,968
Dr. Michael Sumners, D.o, D.O
Internal Medicine — Payments: $9,438
Dr. Gunjan Gholkar, M.d, M.D
Internal Medicine — Payments: $7,082
David Tabor, Do, DO
Internal Medicine — Payments: $6,045
Dr. Soheil Assar, Do, DO
Internal Medicine — Payments: $2,492
Dr. Lucas Watts, D.o, D.O
Internal Medicine — Payments: $1,807